BioSpace News Archive

Agile Therapeutics, Inc., a women’s healthcare company, announced that it has paid-off the remainder of its debt facility with Perceptive Advisors.

Dyne Therapeutics, Inc. announced that management is scheduled to participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 8:30 a.m. ET.

Recce Pharmaceuticals Ltd announced a poster presentation of data from a Phase 1 study evaluating the safety of its lead asset, RECCE® 327, at the American Society for Clinical Pharmacology & Therapeutics 2024 Annual Meeting taking place March 27-29, 2024, in Colorado Springs, Colorado.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the successful launch of its new “Fair Deal Agreement” for the SRT-100 Vision™ (IG-SRT) at the AAD 2024 Annual Meeting, held March 8-12 in San Diego.

Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and highlighted recent corporate progress.

Kazia Therapeutics Limited is pleased to announce the presentation of new data for both its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, from 5-10 April 2024.

Takeda today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP).

SetPoint Medical Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS).

The Max Foundation and BeiGene today announced that the first doses of BRUKINSA® (zanubrutinib) have been administered for the treatment of adult patients with chronic lymphocytic leukemia (CLL) to patients in Armenia and Nepal, as part of a three-year collaboration to provide access to the medicine in 29 low- and middle-income countries (LMICs).

Fabric Genomics is announcing a new partnership with Intermountain Children’s Health to analyze the whole genomes of children sequenced by the Broad Clinical Labs to help speed diagnosis of kids who may have genetic diseases.